menu
    • menu

    Company profile for Aktis Oncology

    NEW Drugs in Dev: 4
    Coral

    Virtual Booth

    Contact Supplier

    China’s top API & intermediate manufacturer, delivering advanced CMO/CDMO solutions to 60+ countries, empowering global health progress

    Virtual Booth

    Contact Supplier

    AMI Lifesciences is Driven by Chemistry. Powered by People.

    Virtual Booth

    Contact Supplier

    ChemWerth works in generic API development & supply, non-infringement patent strategy development and regulatory support.

    Virtual Booth

    Contact Supplier

    Alchem offers Botanical APIs for Pharmaceuticals, Cosmetics and Nutraceuticals// FDA-inspected and EU-GMP certified.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital with its seasoned team of entrepreneurs and drug developers, Aktis has developed proprietary platforms to generate tumor targeting agents with ideal properties for radiotherapy. Designed for high tumor penetration a...
    Aktis Oncology is a biotechnology company pioneering the discovery and development of a new class of targeted radiopharmaceuticals to treat a broad range of solid tumor cancers. Founded and incubated by MPM Capital with its seasoned team of entrepreneurs and drug developers, Aktis has developed proprietary platforms to generate tumor targeting agents with ideal properties for radiotherapy. Designed for high tumor penetration and long residence time, Aktis Oncology’s molecules can quickly clear other areas of the body, thereby maximizing tumor elimination while minimizing side effects of treatment.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Aktis OncologyUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    17 Drydock Avenue, Suite #17-401, Boston, MA 02210
    Telephone
    Telephone
    202.930.4762
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.aktisoncology.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    PEGS Boston Summit

    PEGS Boston Summit

    Not Confirmed

    envelop Contact Supplier

    PEGS Boston Summit

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    Aktis Oncology To Present At Jefferies Healthcare Conference
    Aktis Oncology To Present At Jefferies Healthcare Conference

    27 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/27/3302365/0/en/aktis-oncology-to-present-at-the-jefferies-global-healthcare-conference.html

    GLOBENEWSWIRE
    27 May 2026
    Share Share
    Aktis Oncology Reports First-in-Human AKY-2519 Tumor Uptake Data
    Aktis Oncology Reports First-in-Human AKY-2519 Tumor Uptake Data

    21 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/21/3299806/0/en/aktis-oncology-reports-first-in-human-clinical-imaging-and-dosimetry-data-for-aky-2519-demonstrating-robust-tumor-uptake-and-limited-normal-tissue-exposures-in-patients-with-b7-h3-.html

    GLOBENEWSWIRE
    21 May 2026
    Share Share
    Aktis Oncology Unveils Q1 2026 Financials And Business Highlights
    Aktis Oncology Unveils Q1 2026 Financials And Business Highlights

    11 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/11/3292282/0/en/aktis-oncology-reports-financial-results-and-business-highlights-for-first-quarter-2026.html

    GLOBENEWSWIRE
    11 May 2026
    Share Share
    Aktis Oncology to Present at BofA Health Care Conference
    Aktis Oncology to Present at BofA Health Care Conference

    06 May 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/05/06/3288736/0/en/aktis-oncology-to-present-at-the-bofa-securities-health-care-conference.html

    GLOBENEWSWIRE
    06 May 2026
    Share Share
    Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519
    Aktis Oncology Initiates Phase 1b Clinical Trial for AKY-2519

    04 May 2026

    // FIRSTWORD PHARMA

    https://firstwordpharma.com/story/7268156

    FIRSTWORD PHARMA
    04 May 2026
    Share Share
    Aktis to Present AKY-2519 Dosimetry Data at 2026 ASCO
    Aktis to Present AKY-2519 Dosimetry Data at 2026 ASCO

    21 Apr 2026

    // GLOBENEWSWIRE

    https://www.globenewswire.com/news-release/2026/04/21/3278532/0/en/aktis-oncology-announces-presentation-of-first-clinical-imaging-and-dosimetry-data-for-aky-2519-at-the-2026-american-society-of-clinical-oncology-asco-annual-meeting.html

    GLOBENEWSWIRE
    21 Apr 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search